Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion

Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion

Hemorrhagic side effects are the bane of oral anticoagulation. Despite careful selection of medications and close monitoring, some adverse events are unavoidable. The available literature about the risks of triple oral anticoagulation therapy versus dual antiplatelet therapy does not address all of...

Full description

Bibliographic Details
Main Authors: Dane D. Gruenebaum, Ahmad Alsarah, Osama Alsara, Heather Laird-Fick
Format: Article
Language:English
Published: Hindawi Limited 2014-01-01
Series:Case Reports in Cardiology
Online Access:http://dx.doi.org/10.1155/2014/293476
id doaj-e740944c4bb14294a1b7597bad64c624
record_format Article
spelling doaj-e740944c4bb14294a1b7597bad64c6242020-11-24T22:44:11ZengHindawi LimitedCase Reports in Cardiology2090-64042090-64122014-01-01201410.1155/2014/293476293476Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General DiscussionDane D. Gruenebaum0Ahmad Alsarah1Osama Alsara2Heather Laird-Fick3Department of Internal Medicine, Michigan State University, B-301 Clinical Center, East Lansing, MI 48824, USADepartment of Internal Medicine, Michigan State University, B-301 Clinical Center, East Lansing, MI 48824, USADepartment of Internal Medicine, Michigan State University, B-301 Clinical Center, East Lansing, MI 48824, USADepartment of Internal Medicine, Michigan State University, B-301 Clinical Center, East Lansing, MI 48824, USAHemorrhagic side effects are the bane of oral anticoagulation. Despite careful selection of medications and close monitoring, some adverse events are unavoidable. The available literature about the risks of triple oral anticoagulation therapy versus dual antiplatelet therapy does not address all of the medication combinations currently available. This report describes a patient with atrial fibrillation and recent stent placement who developed severe, recurrent epistaxis on aspirin, prosugrel, and rivaroxaban. We believe this is the first case report of severe bleeding with this combination, and it may help provide insights into the risk for other patients.http://dx.doi.org/10.1155/2014/293476
collection DOAJ
language English
format Article
sources DOAJ
author Dane D. Gruenebaum
Ahmad Alsarah
Osama Alsara
Heather Laird-Fick
spellingShingle Dane D. Gruenebaum
Ahmad Alsarah
Osama Alsara
Heather Laird-Fick
Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
Case Reports in Cardiology
author_facet Dane D. Gruenebaum
Ahmad Alsarah
Osama Alsara
Heather Laird-Fick
author_sort Dane D. Gruenebaum
title Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
title_short Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
title_full Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
title_fullStr Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
title_full_unstemmed Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
title_sort bleeding complication of triple therapy of rivaroxaban, prasugrel, and aspirin: a case report and general discussion
publisher Hindawi Limited
series Case Reports in Cardiology
issn 2090-6404
2090-6412
publishDate 2014-01-01
description Hemorrhagic side effects are the bane of oral anticoagulation. Despite careful selection of medications and close monitoring, some adverse events are unavoidable. The available literature about the risks of triple oral anticoagulation therapy versus dual antiplatelet therapy does not address all of the medication combinations currently available. This report describes a patient with atrial fibrillation and recent stent placement who developed severe, recurrent epistaxis on aspirin, prosugrel, and rivaroxaban. We believe this is the first case report of severe bleeding with this combination, and it may help provide insights into the risk for other patients.
url http://dx.doi.org/10.1155/2014/293476
work_keys_str_mv AT danedgruenebaum bleedingcomplicationoftripletherapyofrivaroxabanprasugrelandaspirinacasereportandgeneraldiscussion
AT ahmadalsarah bleedingcomplicationoftripletherapyofrivaroxabanprasugrelandaspirinacasereportandgeneraldiscussion
AT osamaalsara bleedingcomplicationoftripletherapyofrivaroxabanprasugrelandaspirinacasereportandgeneraldiscussion
AT heatherlairdfick bleedingcomplicationoftripletherapyofrivaroxabanprasugrelandaspirinacasereportandgeneraldiscussion
_version_ 1725692518241140736

Similar Items